Drug intelligence / Profile preview

CTN XR1

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

CTN XR1 refers to an extended-release (XR) tablet formulation containing 400 mg of CTN, administered orally. It is being investigated in a Phase 1 clinical study to assess its safety, tolerance, and the effect of food on its pharmacokinetics. The specific identity of "CTN" as a chemical or generic drug name is not clarified in the available sources; it appears to be a code name for an investigational compound or formulation under study. The primary indication for this formulation is not explicitly stated in the search results, but it is being evaluated as part of early-phase clinical research[1].

Beyond the preview

Go deeper on CTN XR1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTN XR1.

Explore the full profile